Nektar Therapeutics Gains New Life On Buyout Rumors & Atopic Dermatitis Breakthrough
Neogen’s New CEO Wastes No Time—Stock Soars on Restructuring Blitz!
Neogen Corporation shares jumped 23% after solid Q1 results and a new cost-cutting plan that trims 10% of its workforce, signaling a focused turnaround under new leadership after a tough year.
IBM Beats Expectations but Falls as Investors Zero In on Slowing Cloud Growth
Stock Market Today: Stocks Rise as Oil Prices Surge and Earnings Roll In After Tesla’s Mixed Results
McEwen Grabs Canadian Gold: Can Tartan Lake Fuel Its 2030 Gold Ambitions?
Business & Market Movers
Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023
Deep Dive & Research
Healthcare & Biotech
Nektar Therapeutics Gains New Life On Buyout Rumors & Atopic Dermatitis Breakthrough
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds.
Harrow’s MELT Acquisition Could Disrupt IV Sedation—But Is It The Hottest Pharma Small-Cap Buy?
Zepp Health’s Bet On Women’s Health With The Wild.AI Buyout: Strategic Leap Or Risky Play?
Phreesia’s $160 Million AccessOne Acquisition: Will This Deal Redefine Healthcare Payments?
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape
Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story
Tech & Energy
IBM Beats Expectations but Falls as Investors Zero In on Slowing Cloud Growth
IBM shares took a dive on Thursday despite stronger-than-expected third-quarter earnings and revenue. Investors have turned their focus to signs of cooling growth in the company’s software and hybrid cloud businesses.
OpenAI and Broadcom Strike Multibillion-Dollar Deal to Build 10 Gigawatts of Custom AI Chips
